March 1st, 2015- Dr. Suzanne Stratton has been involved with both academic and commercial ‘bench-to-bedside’ research for over 20 years. After working in the biotech industry in cancer gene therapy she earned her doctorate from the Interdisciplinary Graduate Program in Cancer Biology at the University of Arizona (U of A), Arizona Cancer Center. Her foci were in the molecular biology and protein biochemistry of solid tumors. Following graduate school Dr. Stratton became a faculty at the U of A College of Medicine and Director of the Prostate Cancer Prevention Program for which she earned NIH, DoD and private funding to support infrastructure, laboratory research and clinical trials studying prostate cancer chemoprevention and prognostication. She was a voting member of the U of A Human Subjects Protection Program (IRB) and served for three years as Chair during which time the Committee earned AAHRP accreditation. Following her tenure at U of A, she became the Vice President for Research at the Carle Foundation Hospital, the teaching hospital at the University of Illinois, where she also served as faculty in the College of Medicine. During her career, Dr Stratton has been accountable for leadership in post-graduate training programs in medical residencies, oncology fellowships; and, education for physician researchers in addition to mentoring doctoral and post-doctoral students in translational research. She also has been accountable for building Scientific Review Committees to serve interdisciplinary programs and IRB reform. Her procurement of funds and fundraising activities have been responsible for development of a new Fellowship in Translational Medicine and an Adult Stem Cell facility at University of Illinois and a biospecimen repository. She has held other academic appointments and leadership roles in hybrid organizations, participated in development of medical policy and coverage decisions with the Blue Cross Blue Shield Association; and, has sat on numerous grant review panels for the NIH, DoD and private foundations. Because of her expertise in bench-to-bedside drug development, throughout her career she has been instrumental as leadership for start-up companies with new therapeutic and cosmetic agents; and, for teaching, community and hybrid hospitals in building and growing their translational and clinical research programs.